CJC-1295: one trial, from 2006, and nothing since
There is exactly one randomized trial of CJC-1295 in the literature. It was published in 2006, it ran in healthy adults, it measured hormone levels rather than anything a person would feel, and it reported no serious adverse reactions. The FDA's entry on the same peptide says the agency has identified serious adverse events, including raised heart rate and a systemic vasodilatory reaction. Both of those are on the record, and the twenty years between them is the story.
What this comes down to
- One randomized trial, published in the Journal of Clinical Endocrinology and Metabolism in 2006. Nothing since.
- It measured growth hormone and IGF-I, not body composition, recovery or sleep. Growth hormone rose 2- to 10-fold and IGF-I 1.5- to 3-fold, with a half-life of about six to eight days.
- The trial reported no serious adverse reactions. The FDA's compounding entry names increased heart rate and systemic vasodilatory reaction as serious adverse events it has identified.
- It is sold almost exclusively as a blend with ipamorelin, a combination no trial has tested.
What the one trial did
CJC-1295 is a growth-hormone-releasing hormone analog engineered to last. It has 33 indexed records and exactly one randomized trial[3]. The 2006 paper reports two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, one running 28 days and the other 49[1]. A single subcutaneous injection produced dose-dependent rises in mean plasma growth hormone of two- to tenfold lasting six days or more, and in IGF-I of 1.5- to threefold lasting nine to eleven days. The estimated half-life was 5.8 to 8.1 days. After repeat dosing, mean IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported.
Tenfold is a large number and it describes a hormone concentration, not an outcome. Nothing in that trial measured muscle, fat, sleep, recovery or how anyone felt. The paper's own conclusion is that the data support the potential utility of CJC-1295 as a therapeutic agent — which is the sentence a phase 1 result earns, and is where the program appears to have stopped.
PubMed, via the E-utilities API
("CJC-1295"[tiab] OR "CJC 1295"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]Returned 1. Positive control — semaglutide, identical filter — returned 316 through the identical filter in the same session.
Unfiltered, the name returns 33 records across both spellings. A closer control, tesamorelin — the same hormone axis, the same class of molecule — returned 26 randomized trials through the identical filter, so the filter finds trials of GHRH analogs when they exist.
What the FDA has that the trial does not
The agency's compounding page, face-dated April 22, 2026, carries a short entry that does not match the trial's safety line[2].
“Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
[2]
The two are not in conflict in the way they first look. A 2006 trial in a few dozen healthy volunteers is not powered to find an uncommon serious event, and the FDA is not restricted to published trials — it sees adverse event reports. What the pairing tells you is that the total human safety base for this peptide is one small trial plus whatever the agency has in its files, and neither is large. The entry sits in the withdrawn-nominations table, which removes the substance from the queue for the bulks list and leaves the text published. Our status table records that placement for every peptide on these menus.
Nobody sells it alone
Across the 190 sellers we have read first-hand, one priced line names CJC-1295, and it is the same blended protocol that carries ipamorelin, from Live Vital. That is worth holding onto when a page cites the 2006 numbers at you: the trial gave CJC-1295 by itself. The ipamorelin record is separate, and it is a trial that missed. Adding them together produces a product neither result describes.
There is no approved product with CJC-1295 as an active ingredient — we queried Drugs@FDA by ingredient, and in the same run a fabricated ingredient name returned the same empty result while tesamorelin returned one application and glutathione two[4]. So what a company dispenses is a compounded preparation, and the compounding questions apply: which pharmacy, which grade of material, and what any testing they mention actually covered.
Questions people actually ask
How many trials of CJC-1295 are there?
One, published in 2006, covering two randomized placebo-controlled ascending-dose studies in healthy adults. No randomized trial of CJC-1295 has been indexed since, while the identical filter finds 26 for tesamorelin, a drug on the same hormone axis.
Did the trial show CJC-1295 builds muscle or burns fat?
It did not measure either. The endpoints were plasma growth hormone and IGF-I concentrations and standard pharmacokinetic parameters. Body composition, strength, sleep and recovery were not assessed.
Is CJC-1295 safe?
The single published trial reported no serious adverse reactions at the doses tested. The FDA states separately that it has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited.
What is the difference between CJC-1295 and tesamorelin?
Both are growth-hormone-releasing hormone analogs. Tesamorelin finished a development program and is the active ingredient of an approved product with 26 randomized trials behind it. CJC-1295 has one trial from 2006 and no approval.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism, 2006. PMID 16352683 · doi:10.1210/jc.2005-1536Two randomized, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61 found dose-dependent increases in mean plasma growth hormone of 2- to 10-fold for six days or more and in IGF-I of 1.5- to 3-fold for nine to eleven days, an estimated half-life of 5.8 to 8.1 days, IGF-I above baseline for up to 28 days after multiple doses, and no serious adverse reactions.
- 2.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026CJC-1295 appears in the withdrawn-nominations table with the agency's text stating that it has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited.
- 3.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-11, CJC-1295 returned 33 records across both spellings and 1 randomized controlled trial with the human indexing tag, against 316 for semaglutide and 26 for tesamorelin through the identical filter in the same session.
- 4.Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. SourceNo approved product lists CJC-1295 as an active ingredient; a fabricated ingredient name returned the same empty result in the same run, while tesamorelin returned one application and glutathione two.
Key figures